D.E. Shaw & Co’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
D.E. Shaw & Co's TGTX Position: Q3 2026 in Review
D.E. Shaw & Co reduced its TG Therapeutics (TGTX) stake by 3.6% in Q3 2026, selling an estimated $6.58M and leaving 3,279,204 shares worth $183M. The position accounts for 0.09% of the portfolio, ranked #253.
D.E. Shaw & Co first reported a position in TGTX in Q1 2015 and has held it in 41 quarters since. The position peaked at $187M in Q2 2026. 454 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.
- D.E. Shaw & Co held 3,279,204 shares of TG Therapeutics worth $183M as of Q3 2026.
- D.E. Shaw & Co sold 121,604 TG Therapeutics shares in Q3 2026, an estimated $6.58M.
- TG Therapeutics made up 0.09% of D.E. Shaw & Co's portfolio in Q3 2026, its #253 holding.
- D.E. Shaw & Co first reported a position in TG Therapeutics in Q1 2015 and has held it in 41 quarters since.
- D.E. Shaw & Co's TG Therapeutics position peaked at $187M in Q2 2026.
- 454 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.
Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.